Overall, PET imaging with PSMA-targeting radiopharmaceuticals demonstrated slightly superior performance compared to CT and MRI for detecting hepatic and extrahepatic HCC lesions [28,30,31,32]; moreover, it was observed that radiopharmaceutical uptake was significantly higher in contrast-enhancing tumor areas than in non-enhancing ones [28]. Here, FOLH1 is linked to hepatocellular carcinoma.